Published Jun 12, 2019

Harbour BioMed and Erasmus MC Sign MoU to Advance Next-Generation Immuno-oncology, and Immunology Drug Discovery and Clinical Development

Member News
Copy The Link to the  Article
Harbour BioMed and Erasmus MC Sign MoU to Advance Next-Generation Immuno-oncology, and Immunology Drug Discovery and Clinical Development
Copy The Link to the  Article

Related or similar articles

View more News
June 13, 2024

Advancing Science at Labshares: Diagonal Therapeutics' Journey

Labshares News
December 9, 2021

Bulfinch Leases 40,000 Square Feet to Labshares

BOSTON & NEWTON, Mass.--(BUSINESS WIRE)--The Bulfinch Companies, Inc. (Bulfinch), a commercial real estate and investment firm, and Labshares Newton today announced the expansion of the life science and biotech co-working incubator at Chapel Bridge..
Labshares News
June 18, 2024

Labshares Announces Key Leadership Additions: Devon Lagasse Joins as VP of Growth and Emma Orfanos Is Promoted to Manager of Business Development

Press Releases